Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer
SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therap...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2022-12, Vol.28 (24), p.5238-5240 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5240 |
|---|---|
| container_issue | 24 |
| container_start_page | 5238 |
| container_title | Clinical cancer research |
| container_volume | 28 |
| creator | Miller, Kathryn M Friedman, Claire F |
| description | SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297. |
| doi_str_mv | 10.1158/1078-0432.CCR-22-1779 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2700639726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-f02c4393ac7456684a206a899203136a3e7a3a815a6df7c02700713970c1b9553</originalsourceid><addsrcrecordid>eNpVUVtLwzAUDqJ4mf4EpY--dObSJK0vshUvg6Eg-hzOstRV26Ym7WD_3pS5oU8ncL7LyfchdEnwmBCe3hAs0xgnjI7z_DWmNCZSZgfolHAuY0YFPwzvHeYEnXn_iTFJCE6O0QnjWSJxwk_RbFoWfaO70jZQRdPK6i9YmttoEj3btamiWV33je1WxkG7iSZt6yzoVVRYF-XGrUsdWDk02rhzdFRA5c3F7xyh94f7t_wpnr88zvLJPNZM4C4uMNUJyxhomXAh0gQoFpBmGcWMMAHMSGCQEg5iWUiNqcRYEpZJrMki45yN0N1Wt-0XtVlq03QOKtW6sga3URZK9X_TlCv1YdeKhP-nKaFB4fpXwdnv3vhO1aXXpqqgMbb3arAUwZGKAOVbqHbWe2eKvQ_BauhBDRmrIWMVelCUqqGHwLv6e-SetQue_QB_noK-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2700639726</pqid></control><display><type>article</type><title>Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Miller, Kathryn M ; Friedman, Claire F</creator><creatorcontrib>Miller, Kathryn M ; Friedman, Claire F</creatorcontrib><description>SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-22-1779</identifier><identifier>PMID: 35947045</identifier><language>eng</language><publisher>United States</publisher><subject>Antibodies, Bispecific - therapeutic use ; B7-H1 Antigen - immunology ; Female ; Humans ; Immunotherapy ; Neoplasm Recurrence, Local ; Transforming Growth Factor beta ; Uterine Cervical Neoplasms - therapy</subject><ispartof>Clinical cancer research, 2022-12, Vol.28 (24), p.5238-5240</ispartof><rights>2022 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c360t-f02c4393ac7456684a206a899203136a3e7a3a815a6df7c02700713970c1b9553</cites><orcidid>0000-0003-2621-8553 ; 0000-0002-7464-1981</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3356,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35947045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, Kathryn M</creatorcontrib><creatorcontrib>Friedman, Claire F</creatorcontrib><title>Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.</description><subject>Antibodies, Bispecific - therapeutic use</subject><subject>B7-H1 Antigen - immunology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Transforming Growth Factor beta</subject><subject>Uterine Cervical Neoplasms - therapy</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUVtLwzAUDqJ4mf4EpY--dObSJK0vshUvg6Eg-hzOstRV26Ym7WD_3pS5oU8ncL7LyfchdEnwmBCe3hAs0xgnjI7z_DWmNCZSZgfolHAuY0YFPwzvHeYEnXn_iTFJCE6O0QnjWSJxwk_RbFoWfaO70jZQRdPK6i9YmttoEj3btamiWV33je1WxkG7iSZt6yzoVVRYF-XGrUsdWDk02rhzdFRA5c3F7xyh94f7t_wpnr88zvLJPNZM4C4uMNUJyxhomXAh0gQoFpBmGcWMMAHMSGCQEg5iWUiNqcRYEpZJrMki45yN0N1Wt-0XtVlq03QOKtW6sga3URZK9X_TlCv1YdeKhP-nKaFB4fpXwdnv3vhO1aXXpqqgMbb3arAUwZGKAOVbqHbWe2eKvQ_BauhBDRmrIWMVelCUqqGHwLv6e-SetQue_QB_noK-</recordid><startdate>20221215</startdate><enddate>20221215</enddate><creator>Miller, Kathryn M</creator><creator>Friedman, Claire F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2621-8553</orcidid><orcidid>https://orcid.org/0000-0002-7464-1981</orcidid></search><sort><creationdate>20221215</creationdate><title>Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer</title><author>Miller, Kathryn M ; Friedman, Claire F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-f02c4393ac7456684a206a899203136a3e7a3a815a6df7c02700713970c1b9553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Bispecific - therapeutic use</topic><topic>B7-H1 Antigen - immunology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Transforming Growth Factor beta</topic><topic>Uterine Cervical Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, Kathryn M</creatorcontrib><creatorcontrib>Friedman, Claire F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, Kathryn M</au><au>Friedman, Claire F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2022-12-15</date><risdate>2022</risdate><volume>28</volume><issue>24</issue><spage>5238</spage><epage>5240</epage><pages>5238-5240</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.</abstract><cop>United States</cop><pmid>35947045</pmid><doi>10.1158/1078-0432.CCR-22-1779</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-2621-8553</orcidid><orcidid>https://orcid.org/0000-0002-7464-1981</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2022-12, Vol.28 (24), p.5238-5240 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018812 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies, Bispecific - therapeutic use B7-H1 Antigen - immunology Female Humans Immunotherapy Neoplasm Recurrence, Local Transforming Growth Factor beta Uterine Cervical Neoplasms - therapy |
| title | Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A00%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bifunctional%20Blockade:%20A%20Novel%20Immunotherapy%20Approach%20for%20Cervical%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=Miller,%20Kathryn%20M&rft.date=2022-12-15&rft.volume=28&rft.issue=24&rft.spage=5238&rft.epage=5240&rft.pages=5238-5240&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-22-1779&rft_dat=%3Cproquest_pubme%3E2700639726%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2700639726&rft_id=info:pmid/35947045&rfr_iscdi=true |